These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21291477)

  • 1. The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future.
    Zavras AI
    Ann N Y Acad Sci; 2011 Feb; 1218():55-61. PubMed ID: 21291477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and osteonecrosis of the jaws.
    Mariotti A
    J Dent Educ; 2008 Aug; 72(8):919-29. PubMed ID: 18676801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the clinical implications of bisphosphonates in dentistry.
    Borromeo GL; Tsao CE; Darby IB; Ebeling PR
    Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteonecrosis of the jaw and bisphophonates in oncology].
    Facon T; Bensadoun RJ; Blanc JL; Confavreux C; Gourmet R; Maes JM; Penel G; Vieillard MH; Woeller A
    Bull Cancer; 2008 Apr; 95(4):413-8. PubMed ID: 18495570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw.
    Chu V; ;
    Hawaii Dent J; 2008; 39(5):9-12; quiz 17. PubMed ID: 19189512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bisphosphonates (BP) and osteonecrosis of the jaws; should administration of BP be discontinued at the early phase?].
    Urade M
    Clin Calcium; 2010 Nov; 20(11):1740-3. PubMed ID: 21066911
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
    Mawatari T
    Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
    Gutta R; Louis PJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis.
    Jeffcoat M; Watts NB
    Gen Dent; 2008; 56(1):96-102; quiz 103-4, 111-2. PubMed ID: 18254568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.